应用P38抑制剂降低结肠癌细胞AKT的表达  

The application P38 inhibitor reduces the AKT expression in colon cancer cell line

作　　者：张军[1] 张玲利[1] 李金鹏[1] 于红刚[1] 

机构地区：[1]武汉大学人民医院消化内科,湖北武汉430060

出　　处：《胃肠病学和肝病学杂志》2012年第11期1011-1013,共3页Chinese Journal of Gastroenterology and Hepatology

基　　金：中央高校基本科研业务费专项资金(201130202020017)

摘　　要：目的探讨P38抑制剂SB203580对顺铂杀伤作用及耐药性产生的影响。方法以结肠癌细胞HCT-116为实验对象。设定P38MAPK特异性抑制剂SB203580的浓度20 mg/L、顺铂的浓度100μmol/L,两者合用处理结肠癌HCT-116细胞株。MTT法和流式细胞术检测顺铂(Ⅰ组)和SB203580+顺铂(Ⅱ组)对结肠癌细胞株HCT-116生长及凋亡的影响,RT-PCR检测顺铂和SB203580+顺铂在转录水平上AKT的表达。结果顺铂与SB203580联合后对HCT-116细胞增殖的抑制及致凋亡作用显著增强;顺铂与SB203580联合后可以显著降低AKT的表达水平。结论 SB203580提高顺铂对结肠癌细胞株HCT-116的杀伤效果及降低顺铂耐药性的产生。Objective To evaluate the sensitive effect and the possible mechanisms of chemoresisitance of SB203580, a p38MAPK inhibitor, on colon cancer cell line HCT-116 when combined with cisplatin. Methods Colon cancer cells HCT-116 were used as experimental subjects. The concentration of SB203580 was setted to 20 mg/L, the concentration of cisplatin was 100 μmol/L. After treatment, MTT was used to measure inhibitory effects, flow cytometry was used to investigate the apoptosis of HCT-116 and AKT was detected by RT-PCR. Results After combined group of SB203580 and cisplatin, the growth inhibition rate of HCT-116 cells was significantly increased compared with cisplatin group and SB203580 group. The apoptotic rate was also significantly increased when cisplatin combined with SB203580. The AKT expression was significantly higher in the cisplatin group than in combination group. Conclusion SB203580 could reduced the AKT expression and sensitized cisplatin on its lethal effect of HCT-116 cells.

关 键 词：结肠癌 顺铂 耐药性 

分 类 号：R574.62[医药卫生—消化系统]